Zacks Research Expects Higher Earnings for Bausch Health Cos

Bausch Health Cos Inc. (NYSE:BHC) – Investment analysts at Zacks Research boosted their FY2027 EPS estimates for shares of Bausch Health Cos in a research note issued on Tuesday, September 22nd. Zacks Research analyst Team now forecasts that the company will earn $3.85 per share for the year, up from their prior forecast of $3.84. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.35 per share. Zacks Research also issued estimates for Bausch Health Cos’ FY2028 earnings at $3.05 EPS.

Bausch Health Cos (NYSE:BHC) last posted its quarterly earnings data on Wednesday, July 29th. The company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.30. The company had revenue of $2.83 billion for the quarter, compared to the consensus estimate of $2.59 billion. Bausch Health Cos had a negative net margin of 10.12% and a negative return on equity of 561.95%.

Other analysts also recently issued research reports about the company. Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Weiss Ratings upgraded Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, July 31st. Finally, Jefferies Financial Group upgraded Bausch Health Cos to a “hold” rating in a research note on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $8.00.

Bausch Health Cos Trading Up 2.9%

Shares of BHC opened at $5.80 on Wednesday. Bausch Health Cos has a 12-month low of $4.33 and a 12-month high of $8.00. The company has a quick ratio of 1.08, a current ratio of 1.44 and a debt-to-equity ratio of 54.68. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -1.96 and a beta of 0.37. The stock’s 50-day moving average price is $5.95 and its 200 day moving average price is $5.50.

Institutional Investors Weigh In On Bausch Health Cos

Institutional investors have recently added to or reduced their stakes in the stock. Tacita Capital Inc bought a new stake in shares of Bausch Health Cos in the 2nd quarter worth about $29,000. Caitong International Asset Management Co. Ltd increased its position in shares of Bausch Health Cos by 25,689.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 10,058 shares of the company’s stock worth $70,000 after purchasing an additional 10,019 shares in the last quarter. MQS Management LLC bought a new position in Bausch Health Cos during the 1st quarter valued at about $94,000. Viewpoint Capital Management LLC bought a new position in Bausch Health Cos during the 1st quarter valued at about $97,000. Finally, Amundi boosted its position in Bausch Health Cos by 61.7% in the first quarter. Amundi now owns 23,983 shares of the company’s stock valued at $130,000 after buying an additional 9,148 shares in the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Aimee Lenar sold 36,827 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total value of $258,893.81. Following the sale, the insider owned 334,853 shares of the company’s stock, valued at $2,354,016.59. The trade was a 9.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is currently owned by insiders.

About Bausch Health Cos

Bausch Health Companies Inc is a multinational specialty pharmaceutical company headquartered in Laval, Quebec. The company develops, manufactures and markets prescription medicines, over-the-counter products and medical devices, with a focus on gastroenterology, neurology, dermatology and other specialty therapeutic areas.

Its portfolio includes gastrointestinal treatments such as Xifaxan, Trulance and Relistor, as well as products for conditions affecting the central nervous system and skin.